CDMO Batch Failure in China: Who Pays for Destroyed Product, Delay, and Lost Launch Windows

Life Sciences & Healthcare Blog · Legal cluster hub

When a CDMO batch fails, three clocks start: the disposition of the material, the root-cause investigation, and the commercial launch calendar. Contracts that only talk about rework leave the money fight unstructured. This article explains how sponsors and biotechs should allocate batch failure risk in CDMO master services agreements, how Chinese courts treat limitation clauses, and what the first ten days of a failure response should look like.

Why batch failure disputes are different

A failed CDMO batch combines technical uncertainty with contractual ambiguity. The material may be destroyed, the process may be at fault, the raw material may be defective, or the specification may be unclear. Each possible cause points to a different party, and the investigation itself takes time that the commercial calendar does not have. The sponsor needs the product for the launch; the CDMO needs to protect its manufacturing reputation and its liability position. The dispute is therefore not only about money but about who controls the narrative of the failure, and the contract determines how that narrative is built.

The regulatory dimension adds another layer. The PRC Drug Administration Law Article 30 places the marketing authorization holder at the centre of regulatory liability: the MAH is responsible for the overall quality of the drug, including the quality of products manufactured by contract manufacturers. This means that even where the CDMO's process failure caused the batch loss, the sponsor as MAH remains answerable to the regulator. The contractual allocation of loss between the sponsor and the CDMO does not change the sponsor's regulatory exposure, which is why the contract must also address regulatory cooperation, document access and inspection readiness.

Statutory framework

Civil Code standard terms and mitigation

The PRC Civil Code Articles 496 and 497 protect the party that accepts standard terms. Article 496 requires the party proposing standard terms to draw the other party's attention to the terms that exempt or limit its liability, and provides that terms that are not brought to the other party's attention may be deemed not to form part of the contract. Article 497 provides that standard terms are invalid where they unreasonably exempt the proposing party from liability, increase the other party's liability, or exclude the other party's main rights. Article 584 limits damages to foreseeable loss, and Article 591 imposes a duty on the injured party to take reasonable measures to mitigate its loss. Together, these provisions mean that a CDMO's limitation clause will be scrutinized for whether it was properly disclosed, whether it is reasonable, and whether the sponsor took steps to mitigate the loss after the failure.

"Article 497 of the PRC Civil Code: Standard terms are invalid where they unreasonably exempt or reduce the liability of the party providing them, increase the liability of the other party, or exclude the main rights of the other party."

Drug Administration Law

The PRC Drug Administration Law Article 30 defines the marketing authorization holder's responsibilities, including the obligation to establish a quality management system that covers the entire lifecycle of the drug and to be responsible for the safety, efficacy and quality of the product. The provision is the regulatory anchor for the sponsor's role in the batch failure investigation, and it supports the contract terms that require the CDMO to cooperate with the sponsor's quality and regulatory obligations.

Enforcement context: the Suzhou limitation clause case

A 2023 contract dispute decided by the Suzhou Intermediate Court illustrates how Chinese courts approach CDMO limitation clauses. The court invalidated a CDMO's liability limitation clause that capped damages at one hundred percent of the service fees, finding that the CDMO's gross negligence in operating temperature controls had ruined the sponsor-supplied API. The court applied the standard terms analysis, concluded that the limitation clause unreasonably exempted the CDMO from liability for the consequences of its gross negligence, and allowed the sponsor's claim for the full value of the destroyed material and the related losses. The case is significant for both sides. For sponsors, it confirms that limitation clauses can be challenged and overcome where the CDMO's conduct amounts to gross negligence. For CDMOs, it confirms that limitation clauses drafted too broadly will not protect them, and that the clause should carve out gross negligence and regulatory false statements expressly.

Allocating risk before the failure

The master services agreement should allocate the key risks before the failure occurs, and the drafting should start with the four questions that dominate disputes.

Who pays for destroyed material

The contract should state what happens to the API, drug product and intermediates when a batch fails. The allocation depends on the cause: if the failure is caused by a process or equipment failure at the CDMO, the CDMO should bear the value of the destroyed material; if the failure is caused by defective raw material supplied by the sponsor, the sponsor should bear the loss. The contract should address the ambiguous middle, including specification ambiguity and process transfer gaps, with a defined default allocation that the parties can live with rather than litigate.

When is tech transfer complete

The definition of technology transfer completion is the source of many batch failure disputes. The contract should define completion by a protocol and a signed checklist, including process performance qualification runs, analytical method transfer and batch record review. Where the sponsor transfers an underdeveloped process that fails in production, the CDMO will argue the process was never ready; where the CDMO fails to follow the transferred process, the sponsor will argue the CDMO was at fault. The signed checklist allocates that ambiguity before the failure.

What the limitation clause covers

The liability limitation clause should be reasonable and targeted: a cap on indirect and consequential loss, a cap on direct loss expressed as a multiple of the service fees, and express carve-outs for gross negligence, wilful misconduct and regulatory false statements. The carve-outs are essential because courts will not enforce a limitation that protects gross negligence, and the sponsor should preserve its ability to claim the full loss in the carve-out scenarios. The clause should also state that it was individually negotiated, with the negotiation record retained, to defeat the standard terms challenge.

What happens to production priority

After a failure, the CDMO may prioritize other clients' production, pushing the sponsor's replacement batch to the end of the queue. The contract should address slot priority after a failure: does the CDMO commit to a defined retry timeline, and what happens if the retry is delayed? The slot priority provision is often the most commercially valuable term in the MSA, because the cost of the delayed launch is usually far higher than the cost of the destroyed material.

The first ten days

The response to a batch failure should follow a defined protocol. Day one to three: quarantine the affected material, arrange dual sampling with the CDMO and an independent laboratory if warranted, and issue a written notice of the failure with a request for the batch records and the investigation plan. Day four to seven: hold the joint investigation meeting, agree on the root-cause analysis framework, and document every finding in writing. The sponsor should not rely on informal communications; a WeChat exchange in which the CDMO's staff speculate that the API was defective becomes the only narrative if nothing else is documented. Day eight to ten: complete the initial root-cause assessment, calculate the material loss, decide whether the CDMO's conduct raises gross negligence issues, and update the commercial plan. Throughout the first ten days, the sponsor should preserve the evidence: the batch records, the temperature logs, the equipment maintenance records and the training records of the personnel involved.

Building the claim and the mitigation record

If the failure leads to a claim, the sponsor should build the file around the four elements that survive judicial scrutiny. First, the contract terms, including the standard term disclosure evidence and the negotiated limitation clause. Second, the technical evidence of cause, including the root-cause analysis, the sampling results and the expert assessment. Third, the loss evidence, including the value of the destroyed material, the incremental manufacturing cost, the delay cost and the lost launch window, each supported by documentation. Fourth, the mitigation record, showing that the sponsor took reasonable steps to limit the loss, including arranging the replacement batch, finding alternative supply and communicating with the regulator and the customers. The mitigation record is required by Civil Code Article 591, and its absence will reduce the recoverable loss even where liability is established.

The regulatory cooperation provisions deserve equal attention. The contract should require the CDMO to notify the sponsor of any regulatory inquiry or inspection related to the failed batch, to provide access to its records and facilities, and to cooperate with the sponsor's regulatory submissions. The MAH's regulatory liability under the Drug Administration Law means that the sponsor cannot treat the CDMO's facility as a black box; the MSA should create the access rights that make the sponsor's oversight real. Where the failure raises patient safety or product quality concerns, the recall and notification obligations should be addressed before the event, with the roles of the sponsor and the CDMO defined.

Read next: CRO/CDMO disputes · License milestones

Part of the life sciences legal cluster · Life sciences blog